BMS to pay up to $1.56bn for Agenus’ bispecific antibody programme by Lucy Parsons | May 20, 2021 | News | 0 BMS will pay Agenus $200m upfront and up to $1.36bn in development, regulatory and commercial milestones Read More
Gilead & Agenus form $1.8bn partnership by Anna Smith | Dec 21, 2018 | News | 0 Gilead Sciences and Agenus have announced a partnership to focus on the development and commercialisation of up to five novel immuno-oncology therapies. Read More